Corrigendum to “Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study” [EBioMedicine 2 (9) (2015) 1133–1144] (S2352396415300712) (10.1016/j.ebiom.2015.07.017));Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study

EBioMedicine

Volumn 2, Issue 9, 2015, Pages 1133-1144

  Ross Adams, H ^a,f   Lamb, Alastair ^a   Dunning, Mark ^f   Halim, S ^a,f   Lindberg, J ^c,i   Massie, Charlie ^f   Egevad, Lars ⁱ   Russell, R ^a,f   Ramos Montoya, A ^a,f   Vowler, Sarah ^f   Sharma, Naomi ^a   Kay, J ^a,e,f   Whitaker, H ^a,e,f   Clark, J ^c,f   Hurst, R ^c,f   Gnanapragasam, V J ^a,b   Shah, Nimish ^a   Warren, Anne ^a   Cooper, Norwich Colin ^c   Lynch, Andy ^f   Stark, R ^a,f   Mills, Ian ^f   Gronberg H ^a,i   Neal, David ^f   Shaw, Greg ^a   Hori, Satoshi ^a   Baridi, Ajoeb ^a   Tran, Maxine ^a   Wadhwa, Karan ^a   Nelson, Adam ^a   Patel, Keval ^a   Thomas, Benjamin ^a   Luxton, Hayley ^a   Gnanpragasam, Vincent ^a   Doble, Andrew ^a   Kastner, Christof ^a   Aho, Tevita ^a   Haynes, Beverley ^a   Partridge, Wendy ^a   Cromwell, Elizabeth ^a   Sangrasi, Asif ^a   Burge, Jo ^a   George, Anne ^a   Stearn, Sara ^a   Corcoran, Marie ^a   Coret, Hansley ^a   Basnett, Gillian ^a   Francis, Indu ^a   Whitington, Thomas ⁱ   Yuan, Yinyin ^f   Rueda, Oscar ^f   Hadfield, James ^f   Howat, Will ^f   Miller, Jodi ^f   Brewer, Daniel ^c   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

ⁱ CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Biochemical relapse; Gene signature; Genomics; Personalised medicine; Prognosis; Prostate cancer; Risk stratification

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; COPY NUMBER VARIATION; DOWN REGULATION; FOLLOW UP; GENE EXPRESSION; GENE FREQUENCY; GENE ONTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE TRAIT LOCUS; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; UPREGULATION; VALIDATION STUDY; CLUSTER ANALYSIS; COHORT ANALYSIS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; METABOLISM; MIDDLE AGED; PROGNOSIS; PROSTATE TUMOR; RECURRENT DISEASE; REPRODUCIBILITY; RISK FACTOR; VERY ELDERLY;

MESSENGER RNA; TRANSCRIPTOME;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; COHORT STUDIES; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84953709298     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2017.03.010     Document Type: Erratum

References (60)

1. Armisén R., Marcelain K., Simon F., et al. TRPM4 enhances cell proliferation through up-regulation of the β-catenin signaling pathway. J. Cell. Physiol. 2011, 226(1):103-109.
2. Attard G., Clark J., Ambroisine L., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27(3):253-263.
3. Barbosa-Morais N.L., Dunning M.J., Samarajiwa S.A., et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res. 2010, 38(3):e17.
4. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 1994, 151(5):1283-1290.
5. Chalise P., Koestler D.C., Bimali M., Yu Q., Fridley B.L. Integrative clustering methods for high-dimensional molecular data. Transl. Cancer Res. 2014, 3(3):202-216.
6. Clark J., Attard G., Jhavar S., et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008, 27(14):1993-2003.
7. Cooper C.S., Eeles R., Wedge D.C., et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 2015, 47(4):367-372.
8. Curtis C., Shah S.P., Chin S.F., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352.
9. Cuzick J., Swanson G.P., Fisher G., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011, 12(3):245-255.
10. Dunning M.J., Smith M.L., Ritchie M.E., Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007, 23(16):2183-2184.
11. Dunning M.J., Curtis C., Barbosa-Morais N.L., Caldas C., Tavare S., Lynch A.G. The importance of platform annotation in interpreting microarray data. Lancet Oncol. 2010, 11(8):717.
12. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother. Rep. 1966, 50(3):125-128.
13. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974, 111(1):58-64.
14. Glinsky G.V., Glinskii A.B., Stephenson A.J., Hoffman R.M., Gerald W.L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 2004, 113(6):913-923.
15. Gorlov I.P., Byun J., Zhao H., Logothetis C.J., Gorlova O.Y. Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development. J. Bioinforma. Comput. Biol. 2012, 10(2):1241013-1241031.
16. Gorlov I.P., Yang J.Y., Byun J., et al. How to get the most from microarray data: advice from reverse genomics. BMC Genomics 2014, 15:223.
17. Grisanzio C., Werner L., Takeda D., et al. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(28):11252-11257.
18. Gundem G., Van Loo P., Kremeyer B., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015, 520(7547):353-357.
19. Hasegawa M., Fujimoto Y., Lucas P.C., et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-κB activation. EMBO J. 2008, 27(2):373-383.
20. Hieronymus H., Schultz N., Gopalan A., et al. Copy number alteration burden predicts prostate cancer relapse. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(30):11139-11144.
21. Holt S.K., Kwon E.M., Lin D.W., Ostrander E.A., Stanford J.L. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate 2010, 70(9):1012-1019.
22. Hong M.K., Macintyre G., Wedge D.C., et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 2015, 6:6605.
23. Hubert L., Arabie P. Comparing partitions. J. Classif. 1985, 2(1):193-218.
24. Irshad S., Bansal M., Castillo-Martin M., et al. A molecular signature predictive of indolent prostate cancer. Sci. Transl. Med. 2013, 5(202):202ra122.
25. Johnson W.E., Li C., Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8(1):118-127.
26. Khanom R.S,.K., Pal S.K., Shimada Y., Morita K., Omura K., Miki Y., Yamaguchi A. Expression of basal cell keratin 15 and keratin 19 in oral squamous neoplasms represents diverse pathophysiologies. Histol. Histopathol. 2012, 27(7):10.
27. Kluth M., Hesse J., Heinl A., et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod. Pathol. 2013, 26(7):975-983.
28. Lamb A.D., Massie C.E., Neal D.E. The transcriptional programme of the androgen receptor (AR) in prostate cancer. BJU Int. 2014, 113(3):358-366.
29. Lalonde E., Ishkanian A.S., Sykes J., et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 2014, 15(13):1521-1532.
30. Li H., Rodriguez-Canales J., Liu W., et al. Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer. Am. J. Pathol. 2013, 183(4):1329-1338.
31. Liu W., Lindberg J., Sui G., et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 2012, 31(35):3939-3948.
32. Liu W., Xie C.C., Thomas C.Y., et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer 2013, 119(13):2405-2412.
33. Lose F., Batra J., O'Mara T., et al. Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urol. Oncol. 2013, 31(5):635-643.
34. Lynch A.G., Chin S.F., Dunning M.J., Caldas C., Tavare S., Curtis C. Calling sample mix-ups in cancer population studies. PLoS One 2012, 7(8):e41815.
35. Markert E.K., Mizuno H., Vazquez A., Levine A.J. Molecular classification of prostate cancer using curated expression signatures. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(52):21276-21281.
36. Massie C.E., Lynch A., Ramos-Montoya A., et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011, 30(13):2719-2733.
37. Meilă M. Comparing clusterings-an information based distance. J. Multivar. Anal. 2007, 98(5):873-895.
38. Mendiratta P., Mostaghel E., Guinney J., et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J. Clin. Oncol. 2009, 27(12):2022-2029.
39. Mo Q., Wang S., Seshan V.E., et al. Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(11):4245-4250.
40. Mottet N., B, P.J., Bellmunt J., van den Bergh R.C.N., Bolla M., van Casteren N.J., Cornford P., Joniau S., Mason M.D., Matveev V., van der Kwast T.H., van der Poel H., Rouvière O., Wiegel T. Guidelines on Prostate Cancer (accessed 20 June 2014). http://www.uroweb.org/gls/pdf/09%20Prostate%20Cancer_LRLV2.pdf.
41. Murtaza M., Dawson S.J., Tsui D.W., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497(7447):108-112.
42. Peduzzi P., Concato J., Feinstein A.R., Holford T.R. Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates. J. Clin. Epidemiol. 1995, 48(12):1503-1510.
43. Ramos-Montoya A., Lamb A.D., Russell R., et al. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol. Med. 2014, 6(5):651-661.
44. Schinke E.N., Bii V., Nalla A., et al. A novel approach to identify driver genes involved in androgen-independent prostate cancer. Mol. Cancer 2014, 13:120-132.
45. Sharma N.L., Massie C.E., Ramos-Montoya A., et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 2013, 23(1):35-47.
46. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. (Article3).
47. Subramanian A., Tamayo P., Mootha V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 2005, 102(43):15545-15550.
48. Sun J., Liu W., Adams T.S., et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007, 67(7):692-700.
49. Taylor B.S., Schultz N., Hieronymus H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18(1):11-22.
50. Tomlins S.A., Mehra R., Rhodes D.R., et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 2007, 39(1):41-51.
51. Van Loo P., Nordgard S.H., Lingjærde O.C., et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(39):16910-16915.
52. Varambally S., Yu J., Laxman B., et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8(5):393-406.
53. Venet D., Dumont J.E., Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput. Biol. 2011, 7(10):e1002240.
54. Wang K., Li M., Hadley D., et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007, 17(11):1665-1674.
55. Warren A.Y., Whitaker H.C., Haynes B., et al. Method for sampling tissue for research which preserves pathological data in radical prostatectomy. Prostate 2013, 73(2):194-202.
56. Williams J.L., Greer P.A., Squire J.A. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. Cancer Gen. 2014, 207(10-12):474-488.
57. Yau C., Mouradov D., Jorissen R.N., et al. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 2010, 11(9):R92.
58. Yin T., Cook D., Lawrence M. ggbio: an R package for extending the grammar of graphics for genomic data. Genome Biol. 2012, 13(8):R77.
59. Yuan Y., Failmezger H., Rueda O.M., et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci. Transl. Med. 2012, 4(157):157ra43.
60. Zhang B., Kirov S., Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005, 33:W741-W748. (Web Server issue).